Introduction {#sec1_1}
============

Coronavirus infection has become a worldwide problem, with millions of infected people and thousands of deaths. Data from the Italian Health Institute indicate that 26% of the coronavirus disease 19 (COVID-19) patients had 1 disease, 26% had 2 diseases, and 47% had 3 or more diseases, and only 1% of the patients had no other disease. The most common chronic pre-existing illnesses were arterial hypertension (76%), ischemic heart disease (37%), atrial fibrillation (26%), and active cancer within the previous 5 years (19%).

As recently reported patients with COVID19 and cancer were more likely to deteriorate into serious illness than those without cancer \[[@B1]\].

The focus of the current manuscript is on patients with an active cancer diagnosis, as these patients require particular clinical attention, starting with the prevention of contact risk for COVID-19 \[[@B2]\].

According to the 2019 data from the Association of Italian Medical Oncology (AIOM), there were 370,000 new cancer diagnoses in Italy, of which 35,000 were prostate cancer diagnoses and 20% were males \>70 years. These numbers are in line with the ones reported from previous years \[[@B3]\]. Therefore, considering the high rate of comorbidities, such as hypertension, diabetes, vascular disease in elderly patients \[[@B4]\] as well as the well-known relationship between old age and prostate cancer \[[@B5]\], there is a considerable need to investigate the clinical risk and aggressiveness of COVID-19 in such patients.

The current manuscript describes the clinical characteristics of 72 prostate cancer patients in South Italy, providing a characteristic snapshot of the Italian prostate cancer patient population during the COVID-19 pandemic in Italy.

Methods {#sec1_2}
=======

All patients with prostate cancer were included in the present study, being treated with hormonal therapy or chemotherapy; regardless of the stage of disease; of being on a day-hospital visit, hospitalized, or on an outpatient visit. The data was collected between March 1 and 27, 2020, at the Tortora Hospital, Pagani, Italy, coincidental to the height of the first wave of the COVID-19 outbreak in Italy.

The Tortora Hospital is a referral hospital with an average of 1,200 genitourinary cancer patients receiving diagnosis or treatment every year. Among those patients, approximately 500 are prostate cancer patients.

The collection of data involved the use of both telephone and in-person pre-triages. Telephone pre-triage was performed the day before cancer therapy by contacting each patient, as previously described \[[@B6]\]. An in-person pre-triage assessment on the day of cancer therapy provided further checks, including a second interview and temperature measurement.

Results {#sec1_3}
=======

Data was collected from all 72 prostate cancer patients attending the Tortora Hospital during the period of the study (March 1--May 27, 2020). The characteristics of the prostate cancer patients who were included in the analysis are shown in Table [1](#T1){ref-type="table"}. Among the 72 patients, 2 patients were confirmed as COVID-19-positive patients (2.8%) (Table [1](#T1){ref-type="table"}) by an reverse transcription-polymerase chain reaction diagnostic test; 0 in the hormone-sensitive (HS) and 2 (8.3%) in castration-resistant prostate cancer (CRPC) setting (*p* \< 0.05).

Of those two COVID-19 positive patients; Patient 1 had non-metastatic CRPC with a 3-month PSA double time (DT), thus defining a rapidly evolving disease. He was being treated with an LHRH agonist. Testosterone was suppressed, so the addition of apalutamide was imminent; however, it was not administered as he had to be admitted to the intensive care unit (ICU). This patient was also being followed-up at Federico II University in Napoli (Urology and Oncology Divisions).

Patient 2 had metastatic CRPC and was receiving LHRH therapy plus enzalutamide (Table [2](#T2){ref-type="table"}). The patient was treated for 15 months with an LHRH agonist; after asymptomatic bone progression in the lumbar spine and pelvis, enzalutamide was added, ongoing from 5 months.

Urgent hospitalization in the ICU was necessary for both patients due to a clinical worsening picture, in the absence of a COVID-19-positive history by contact or by a prior positive test.

At time 0, severe lymphopenia, rising levels of platelets, C-reactive protein, fibrinogen and D-Dimer, as well as a peak in the platelet-to-lymphocyte ratio were observed. After admission, IL-6 decreased from 2,000 pg/mL at baseline to 160 pg/mL. As summarized in Table [2](#T2){ref-type="table"}, Patient 1 developed fever, dyspnea, and a cough while Patient 2 developed dyspnea and a cough, but no fever. Both patients were treated with retroviral therapy from the beginning, followed by antibiotics and chloroquine. Chest computed tomography findings revealed ground-glass opacity.

Intubation with invasive mechanical ventilation in the ICU was required for both patients. Patient 1 also received tocilizumab. Three weeks later, both patients were discharged and returned home after three consecutive negative swab tests.

Discussion {#sec1_4}
==========

Gillessen and Powles\' opinion paper \[[@B7]\]describes how to manage patients with renal, germ-cell, urothelial, and prostate cancer who are COVID-19 positive. The authors concluded that chemotherapy should be delayed and treatment with androgen receptor signaling inhibitors could continue or be prescribed instead of chemotherapy. Based on studies analyzing the frequency of bacterial, viral, and parasitic diseases in patients suffering from hyperglucocorticoidism, testosterone has been shown to have immunosuppressive activity \[[@B8]\].

Therefore, from the literature emerges that testosterone, the most abundant androgen in male organisms, seems to favor the growth of tumors, and in particular prostate cancer due to its negative effect on the immune system which is no longer able to attack the non-self or even generate the pro-inflammatory cytokine cascade \[[@B8]\]. It is possible that suppression of testosterone could lead to upregulation of the immune system, thus resulting in a protective effect against coronavirus infection.

As recently demonstrated by Montopoli et al. \[[@B9]\], prostate cancer patients receiving androgen deprivation therapy had a significantly lower risk of COVID-19 as compared to patients who did not receive androgen deprivation therapy. Our data seem to align with that direction of thought, in the sense that among the HS patients, we have not found any cases, while in a more advanced disease stage, hormone therapy could have a detrimental effect. As suggested by Di Lorenzo, a warning could be issued against androgen receptor signaling inhibitor in the CRPC setting for at least three reasons: concomitant use of prednisone for several months, significant rise in cortisol concentration, and drug interactions \[[@B10]\].

Patient 1 had a rising PSA, a short PSA DT, a low level of testosterone in the blood, and no metastases. Thus, he was considered to be a non-metastatic CRPC patient; therefore, he too received apalutamide. He was being treated with an LHRH agonist. Although apalutamide reduced the levels of testosterone, it could also interfere with retroviral therapy since it is a potent inducer of the CYP450 family \[[@B11]\].

Patient 2 had metastatic CRPC, and so he was treated with an LHRH agonist and enzalutamide. Enzalutamide is an androgen receptor antagonist that suppresses 11β-hydroxysteroid dehydrogenase-2 and increases cortisol levels \[[@B12]\]. This leads to an immunosuppressive effect and a negative outcome in the presence of infection. Moreover, cortisol also decreases the number of lymphocytes, which leads to an increased death rate during infection \[[@B13]\]. Enzalutamide is a potent inducer of the cytochrome P450 (CYP) family such as CYP3A4 and a moderate inducer of CYP2C19 and CYP2C9. In vitro evidence shows that enzalutamide also induces CYP2B6 and uridine 5′-diphospho-glucuronosiltransferase 1A1/4 (UGT1A1/4), contributing to antiretroviral metabolism \[[@B14]\]. Hence, if ritonavir and enzalutamide are administered to the same patient, such as in the case of Patient 2, a lower efficacy of ritonavir could be seen.

Patient 2 was not prescribed abiraterone because he was positive for hepatitis C virus, which is characterized by high levels of transaminases, and it is known that a potential side effect of abiraterone is an increase in transaminases. Further, if co-administered with prednisone, abiraterone can have an immunosuppressive effect \[[@B15]\]. Moreover, chemotherapy was not indicated due to the patient\'s asymptomatic CRPC.

Conclusions {#sec1_5}
===========

Whether hormone therapy, especially in a CRPC setting, has a detrimental or beneficial effect during an aggressive course of COVID-19 remains unknown. Reducing the dose of cancer therapy, interrupting treatment if the cancer is not an aggressive cancer, or changing treatment drugs could be options for the management of prostate cancer patients who are COVID-19 positive \[[@B16]\]. The current manuscript provides the observations from a small sample size of prostate cancer patients. However, these observations seem to align with previously reported results from other parts of the world.

Considering these data an epidemiological study, CO.I.CA. 1 (COVID-19 Infection Cancer patients 1) has been started at several Italian hospitals. The aim of this retrospective/prospective study, which was approved by the relevant ethics committee on April 15, 2020, is to monitor all cancer patients in order to have a better overview of how coronavirus infection influences cancer history.
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###### 

Characteristics of 72 prostate cancer patients

  -------------------------- ------------------
  Median age, years          71 (range 53−82)
  Comorbidity                72 (l00%)
   Hypertension              46
   Diabetes                  20
   Hepatitis B or C          8
   Osteoporosis              5
   Neurologic disorders      5
   Renal dysfunction         2
                             
  At least 2 comorbidities   52 (72%)
                             
  HS disease                 48
                             
  CRPC                       24
                             
  LHRH                       72
                             
  Agonist                    57
                             
  Antagonist                 15
                             
  Abiraterone                4
                             
  Enzalutamide               6
                             
  Apalutamide                7
                             
  Chemotherapy               11
                             
  Docetaxel                  4
                             
  Cabazitaxel                7
  -------------------------- ------------------

###### 

Clinical characteristics of 2 COVID-19-positive patients

  -------------------------------------------------------------------------------------------------------------------------------------------
                                  Patient 1                                               Patient 2
  ------------------------------- ------------------------------------------------------- ---------------------------------------------------
  Age, years                      69                                                      73

                                                                                          

  Comorbidity                     Hypertension[\*](#T2F1){ref-type="table-fn"}            Hypertension[\*](#T2F1){ref-type="table-fn"}

                                  Diabetes                                                Hepatitis C positive

                                  Osteoporosis                                            

                                                                                          

  Cancer Stage                    Stage IV                                                Stage IV

                                  Non-metastatic\                                         Metastatic, castration resistant\
                                  Castration-resistant PSA: 2 ng/mL (PSA DT: 3 months)    PSA 14 ng/mL\
                                                                                          Bone metastases

                                                                                          

  Cancer treatment                LHRH agonist                                            LHRH agonist + enzalutamide

                                                                                          

  Concomitant drugs               Insulin                                                 Angiotensin-converting enzyme

                                  Calcium channel blockers                                inhibitors (ACE)

                                                                                          

  *White blood cell count, µL*                                                            

  Before                          3,800                                                   3,200

  Time 0                          3,200                                                   2,900

  After 2 weeks                   3,700                                                   3,700

                                                                                          

  *Lymphocyte count (% of WBC)*                                                           

  Before                          35%                                                     32%

  Time 0                          15%                                                     16%

  After 2 weeks                   33%                                                     29%

                                                                                          

  *Hemoglobin before*                                                                     

  Time 0                          11.5 g/dL                                               10.4 g/dL

  After 2 weeks                   11.0 g/dL                                               9.4 g/dL

                                  11.4 g/dL                                               9.8 g/dL

                                                                                          

  *Platelets, mm*^3^                                                                      

  Before                          125.000                                                 130.000

  Time 0                          230.000                                                 250.000

  After 2 weeks                   140.000                                                 170.000

                                                                                          

  *C-reactive protein*                                                                    

  Before                          Normal                                                  High

  Time 0                          High                                                    High

                                                                                          

  After 2 weeks                   High                                                    High

                                                                                          

  *IL-6*                                                                                  

  Time 0                          2,000 pg/ mL                                            Unknown

  After 2 weeks                   160 pg/ mL                                              

                                                                                          

  Symptoms                        Fever: 38.7°C for 1 week                                No fever

                                  Dyspnea                                                 Dyspnea

                                  Cough                                                   Cough

                                                                                          

  Duration of hospitalization     3 weeks                                                 3 weeks

                                  Intubation and invasive mechanical ventilation in ICU   Intubation invasive mechanical ventilation in ICU

                                                                                          

  Treatment for COVID-19          Azithromycin                                            Lopinavir/ritonavir

                                  Chloroquine                                             Chloroquine

                                  Heparin                                                 Heparin

                                  Lopinavir-ritonavir                                     Extubated

                                  Tocilizumab                                             

                                  Extubated                                               

                                                                                          

  Survival status                 Alive                                                   Alive
  -------------------------------------------------------------------------------------------------------------------------------------------

Before: 3 weeks before COVID-19 diagnosis. LHRH, luteinizing hormone-releasing hormone; WBC, white blood CELL count; DT: double time.

Grade 2 hypertension according to NCI common toxicity criteria for 5 years.
